A Phase 1 interventional study of AZD7762 and Irinotecan in Advanced Solid Tumors, Cancer and Advanced Solid Malignancies, sponsored by AstraZeneca. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-02-11.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 60 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
AZD7762 monotherapy followed by AZD7762 + irinotecan
Drug: AZD7762 · Drug: Irinotecan
intravenous infusion
intravenous injection
Also known as: Campto®, Camptosar®, irinotecan hydrochloride
The primary objective of this study is to assess the safety and tolerability of AZD7762 alone and in combination with Irinotecan
Time frame: assessed after each course of treatment
To determine the single-dose (after the first single-agent dose) and combination-dose (afer the 2nd combination dose) pharmacokinetics (PK) of AZD7762.
Time frame: assessed after each course of treatment
This study is terminated, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca